Febit has announced the receipt of an EU patent, EP 1 728 860B1, for its technology to synthesise minimal genomes.
The patent protects Febit's technology for combining genes to construct a minimal functional genome or parts of it.
The EU patent complements earlier patents on the synthesis of oligonucleotides for gene assembling.
Febit's portfolio also contains technologies for the exploration of the genome.
Hybselect, for example, is a technology for the enrichment of interesting genes for targeted resequencing.
Febit's miRNA profiling enables the discovery and evaluation of new biomarker signatures for various diseases.
In addition to bioanalytics, the company's intellectual property portfolio predominantly covers the production of synthetic genes on biochips.
